This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Clinical Trials

Confidence in a Treatment that’s setting the standard3-5​​​​​​​

The efficacy and safety of IBRANCE® has been evaluated in two large Randomised Control Trials (RCTs) in women with HR+/HER2- metastatic Breast Cancer (mBC) as part of Pfizer’s robust PALOMA Clinical Trial Programme in Breast Cancer.1-5

PALOMA Clinical Trials Programme

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) PALOMA-2 Clinical Trial results including efficacy and safety outcomes.

Learn more

IBRANCE® Real World Evidence

Real World Evidence (RWE) for IBRANCE® (pabociclib) in advanced breast cancer

Learn more

IBRANCE® Safety Profile

IBRANCE® safety information and frequent adverse events


AI : Aromatase Inhibitor, ER+ / HER2− : Oestrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative, ET : Endocrine Therapy, HR+ / HER2- : Hormone Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative, LHRH : Luteinising Hormone-Releasing Hormone, mBC : metastatic Breast Cancer, RCT: Randomised Controlled Trial, SmPC: Summary of Product Characteristics.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

  1. Rugo HS, et al. Breast Cancer Res Treat. 2019;174:719–29.
  2. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  3. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439. 
  4. Cristofanilli M, et al. ECJ 2018;104:21-31.
  5. Turner NC, et al. N Engl J Med 2018;379:1926–1936 including supplementary appendix.
PP-IBR-GBR-3952. October 2021

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results

  • ​​​​​​​IBRANCE® PALOMA-2 Trial
  • Study Design
  • Efficacy Outcomes
  • Quality of Life Outcomes
  • Safety Profile
  • IBRANCE® Mode of Action


IBRANCE® safety information and outcomes

  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management


  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

Ask Pfizer

Connect virtually with a Pfizer representative to discuss promotional information on a selected range of products.

Book now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021